WO1997028812A3 - Compositions pharmaceutiques destinees au traitement biologique d'infections dues a des souches d'enterococcus faecium resistant aux antibiotiques et notamment a la vancomycine (vre) - Google Patents

Compositions pharmaceutiques destinees au traitement biologique d'infections dues a des souches d'enterococcus faecium resistant aux antibiotiques et notamment a la vancomycine (vre) Download PDF

Info

Publication number
WO1997028812A3
WO1997028812A3 PCT/EP1997/000558 EP9700558W WO9728812A3 WO 1997028812 A3 WO1997028812 A3 WO 1997028812A3 EP 9700558 W EP9700558 W EP 9700558W WO 9728812 A3 WO9728812 A3 WO 9728812A3
Authority
WO
WIPO (PCT)
Prior art keywords
enterococcus faecium
vre
vancomycin
antibiotics
infections
Prior art date
Application number
PCT/EP1997/000558
Other languages
English (en)
Other versions
WO1997028812A2 (fr
Inventor
Herman Goossens
Giuliano Frigerio
Original Assignee
Giuliani S A
Herman Goossens
Giuliano Frigerio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani S A, Herman Goossens, Giuliano Frigerio filed Critical Giuliani S A
Publication of WO1997028812A2 publication Critical patent/WO1997028812A2/fr
Publication of WO1997028812A3 publication Critical patent/WO1997028812A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention a trait à l'emploi d'une souche d'Enterococcus faecium dans la préparation d'un produit à usage médical convenant notamment au traitement d'infections, et tout particulièrement des entéro-colites occasionnées par des souches d'Enterococcus faecium résistant aux antibiotiques et, notamment, à la vancomycine, souches dénommées 'VRE'. On s'est penché, au titre de cette invention, sur Enterococcus faecium, dans la mesure où il appartient à cette souche recensée sous le sigle 'SF68'. L'invention porte également sur des compositions pharmaceutiques utilisées dans un tel cas.
PCT/EP1997/000558 1996-02-08 1997-02-05 Compositions pharmaceutiques destinees au traitement biologique d'infections dues a des souches d'enterococcus faecium resistant aux antibiotiques et notamment a la vancomycine (vre) WO1997028812A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96MI000239A IT1282586B1 (it) 1996-02-08 1996-02-08 Composizioni farmaceutiche per il trattamento biologico delle infezioni dovute a ceppi di enterococcus faecium resistenti agli
ITMI96A000239 1996-02-08

Publications (2)

Publication Number Publication Date
WO1997028812A2 WO1997028812A2 (fr) 1997-08-14
WO1997028812A3 true WO1997028812A3 (fr) 1997-10-02

Family

ID=11373201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/000558 WO1997028812A2 (fr) 1996-02-08 1997-02-05 Compositions pharmaceutiques destinees au traitement biologique d'infections dues a des souches d'enterococcus faecium resistant aux antibiotiques et notamment a la vancomycine (vre)

Country Status (2)

Country Link
IT (1) IT1282586B1 (fr)
WO (1) WO1997028812A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037066A1 (fr) 1996-02-26 1998-08-27 California Institute Of Technology Polyamides ameliores pour assurer une liaison dans le sillon mineur de l'adn a double brins
US5998140A (en) 1996-07-31 1999-12-07 The Scripps Research Institute Complex formation between dsDNA and oligomer of cyclic heterocycles
US6518242B1 (en) 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
CZ301184B6 (cs) 1998-12-23 2009-12-02 Theravance, Inc. Glykopeptidový derivát a farmaceutické prostredky, které jej obsahují
CN1550545A (zh) * 2003-05-15 2004-12-01 肠球菌属乳酸菌以及乳酸菌死菌体的制造方法
CA2536966A1 (fr) * 2003-08-26 2005-03-03 Obschestvo S Ogranichennoi Otvetstvennostyu "Alef-Farma" Utilisation de souches de enterococcus faecium pour traiter l'insuffisance hepatique, pour regenerer et pour intensifier le metabolisme hepatique
KR20070092719A (ko) 2004-11-29 2007-09-13 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 글리코펩타이드 항생 물질 모노머 유도체
CA2623239C (fr) 2005-09-22 2016-07-12 Medivas, Llc Compositions polymeres solides pour administration et methodes d'utilisation de celles-ci
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
US20070280964A1 (en) * 2005-10-06 2007-12-06 Ruth Knorr Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and preventing or treating conjunctivitis
ITMI20060860A1 (it) * 2006-05-02 2007-11-03 Truffini & Regge Farmaceutici Srl Composizioni per lasalute di denti e gengive contenenti microrganismi eubiotici deidratati rivivificabili
KR20100109934A (ko) 2007-12-26 2010-10-11 시오노기세야쿠 가부시키가이샤 글리코펩티드 항생 물질 배당화 유도체
CN102083862A (zh) 2008-04-01 2011-06-01 康奈尔大学 有机-可溶性壳聚糖盐和由其制备的壳聚糖衍生生物材料
IT202200013138A1 (it) * 2022-06-22 2023-12-22 Cerbios Pharma Sa Probiotico per l’uso nel trattamento di alterazioni infiammatorie della mucosa intestinale, in particolare obesità

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1112479B (it) * 1979-04-02 1986-01-13 Giuliani Sa Composizione farmaceutica particolarmente atta alla terapia di enteriti e di affezioni diarroiche generiche
EP0405569A1 (fr) * 1989-06-30 1991-01-02 Cernitin S.A. Produit à activité antimicrobienne, procédé pour son isolement du milieu de culture de streptococcus faecium, et préparation pharmaceutique contenant ce produit à activité antimicrobienne

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1112479B (it) * 1979-04-02 1986-01-13 Giuliani Sa Composizione farmaceutica particolarmente atta alla terapia di enteriti e di affezioni diarroiche generiche
EP0405569A1 (fr) * 1989-06-30 1991-01-02 Cernitin S.A. Produit à activité antimicrobienne, procédé pour son isolement du milieu de culture de streptococcus faecium, et préparation pharmaceutique contenant ce produit à activité antimicrobienne

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 8721, Derwent World Patents Index; Class B05, AN 87-145571, XP002035793 *
EDOUARD LOISEAU: "PLACE DE L'ENTÉROCOQUE SF 68 DANS LA PRÉVENTION ET LE TRAITEMENT DES GASTRO-ENTÉRITES INFECTIEUSES ET LIÉES AUX ANTIBIOTIQUES", REVUE MEDICALE DE LA SUISSE ROMANDE, vol. 114, no. 7, July 1994 (1994-07-01), pages 651 - 654, XP000674785 *
LISA L. DENVER ET AL.: "PERSISTENCE OF VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM GASTROINTESTINAL TRACT COLONIZATION IN ANTIBIOTIC-TREATED MICE", MICROBIAL DRUG RESISTANCE, vol. 2, no. 4, 1996, pages 415 - 421, XP000674789 *
MITRA A K ET AL: "A DOUBLE-BLIND, CONTROLLED TRIAL OF BIOFLORIN (STREPTOCOCCUS FAECIUM SF68) IN ADULTS WITH ACUTE DIARRHEA DUE TO VIBRIO CHOLERAE AND ENTEROTOXIGENIC ESCHERICHIA COLI", GASTROENTEROLOGY, vol. 99, no. 4, October 1990 (1990-10-01), pages 1149 - 1152, XP000670317 *

Also Published As

Publication number Publication date
IT1282586B1 (it) 1998-03-31
ITMI960239A1 (it) 1997-08-08
WO1997028812A2 (fr) 1997-08-14
ITMI960239A0 (fr) 1996-02-08

Similar Documents

Publication Publication Date Title
WO1997028812A3 (fr) Compositions pharmaceutiques destinees au traitement biologique d'infections dues a des souches d'enterococcus faecium resistant aux antibiotiques et notamment a la vancomycine (vre)
BG101118A (en) Therapeutical compounds
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
CA2191213A1 (fr) Souches de lactobacillus d'origine humaine, leurs compositions et leurs utilisations
CA2213302A1 (fr) Methode de prevention et de traitement de lesions du tube digestif dues a la chimio ou a la radiotherapie
CA2145826A1 (fr) Derives de lipopeptide; methode de preparation et utilisation
MX9601069A (es) Nuevas pirido /3,2-e/pirazinonas con efecto antiasmatico y procedimiento para su preparacion.
AU2843689A (en) 2-(2-hydroxy-3-phenoxypropylamino) ethylphenoxymethyl compounds
CA2136331A1 (fr) Nouveaux usages pharmaceutiques d'enzymes de krill
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
AU2967595A (en) Anti-protozoan methods and materials
WO1997005899A3 (fr) Nouveaux vaccins et nouvelles compositions pharmaceutiques utilisant des vesicules de membrane de micro-organismes et leurs procedes d'elaboration
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
HUP9903459A3 (en) Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
WO1996022305A3 (fr) Peptides modifies
AU7761598A (en) 20(s) camptothecin glycoconjugates
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
AU1041397A (en) Antigenic protein originating in malassezia
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
CA2221793A1 (fr) Nouvelle proteine antibacterienne
GR3035710T3 (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation and the use of pharmaceutical preparations based on these compounds as well as medicaments containing them
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
EP0302303A3 (fr) Composés bicycliques, leur utilisation pharmaceutique, leur préparation et intermédiaires pour leur préparation
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97528161

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase